South Africa: Treatment Action Campaign Gives Cautious Welcome to State's HIV . Pagina 1 di 2
Why Is Intelence's U.S. Approval Important? Cal Cohen, M.D., Explains >>
U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION • INTERNATIONAL
South Africa: Treatment Action Campaign Gives Cautious Welcome to State's HIV Guidelines
South Africa's newly released guidelines for preventing mother-to-child HIV
transmission include some improvements but still fall short of World Health Organization recommendations, the AIDS lobby group Treatment Action
The new guidelines call for all HIV-positive pregnant women to be given dual therapy, consisting of a short course of AZT starting in the 28th week of pregnancy and a single dose of nevirapine during labor. Their infants will receive a dose of nevirapine syrup and seven days of AZT, which is more effective than nevirapine on its own -- currently the standard treatment in all provinces except Western Cape, which introduced dual therapy three years ago.
In addition, the guidelines recommend routine HIV testing for all pregnant women visiting antenatal clinics. Babies born to HIV-positive mothers will be screened for the virus at six weeks and at 18 months.
But the guidelines do not change the threshold for initiating long-term therapy, calling for treatment of HIV-positive pregnant women to begin only when their CD4 counts fall below 200, not 350 as activists have urged. TAC expressed disappointment at this decision, noting the health department's own expert committee endorsed the 350 treatment threshold.
The guidelines also do not include using extra drugs to minimize the mother's risk of nevirapine resistance, as proposed by WHO in 2006. TAC noted that Health Minister Manto Tshabalala-Msimang often expressed concern about nevirapine resistance among pregnant women. Her decision not to include a post-delivery, week-long course of AZT and lamivudine "made little sense," TAC said, noting this strategy was "strongly recommended" by HIV pediatricians advising the health department.
Excerpted from: Business Day (Johannesburg) 1.31.2008; Tamar Kahn
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
South Africa: Treatment Action Campaign Gives Cautious Welcome to State's HIV . Pagina 2 di 2
The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are
trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and
HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or
professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a
disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare
“Leber’s hereditary optic neuropathy (LHON): involvement of mitochondrial permeability transition in the pathogenesis and protective actions of minocycline” Summary: Leber’s Hereditary Optic Neuropathy (LHON) is a retinal ganglionic neurodegenerative disorder caused by a maternally inherited mitochondrial DNA point mutation. The dysfunction of complex I of the respiratory chain, af
remote from the final production of the inferential belief (that there is a fire on thehill) for its falsity to infect the latter. Whatever the details may be, the fact doesseem to be that Gan˙ges´a’s theoretical precommitments lead him to an extremelycounterintuitive stance with respect to the ba¯spa¯numa¯na. Certainly, he appears tolack anything like Mandanamis´ra’s elaborate philos